APG Asset Management N.V. Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

APG Asset Management N.V. boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 848.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 227,819 shares of the company’s stock after acquiring an additional 203,792 shares during the period. APG Asset Management N.V. owned 0.06% of Moderna worth $9,148,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. abrdn plc grew its position in shares of Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares in the last quarter. Spire Wealth Management grew its position in Moderna by 2,150.4% during the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock worth $966,000 after buying an additional 22,192 shares in the last quarter. Geode Capital Management LLC increased its stake in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Moderna by 4,418.9% in the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock valued at $6,127,000 after acquiring an additional 144,099 shares in the last quarter. Finally, South Dakota Investment Council boosted its position in shares of Moderna by 4.0% during the 4th quarter. South Dakota Investment Council now owns 299,399 shares of the company’s stock valued at $12,449,000 after acquiring an additional 11,500 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 8.1 %

Moderna stock opened at $24.50 on Friday. The firm has a market cap of $9.47 billion, a P/E ratio of -2.64 and a beta of 2.23. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The firm has a 50-day moving average of $31.72 and a 200-day moving average of $41.27.

Wall Street Analyst Weigh In

MRNA has been the topic of several research analyst reports. Evercore ISI set a $50.00 price objective on shares of Moderna in a research report on Friday, February 14th. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Morgan Stanley cut their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. lowered their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Friday, March 21st. Finally, Bank of America cut their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.